Relmada Therapeutics, Inc. RLMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s cash & equivalents?
- Relmada Therapeutics, Inc. (RLMD) reported cash & equivalents of $9.78M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Relmada Therapeutics, Inc.'s cash & equivalents increased by 750.3% year-over-year, from $1.15M to $9.78M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s cash & equivalents has grown at a 7.0% compound annual growth rate (CAGR), from $2.5M to $3.5M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.